Compare Abeona Therapeutics Inc (ABEO) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Crowdstrike Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Crowdstrike Holdings Inc trades at $188.89 (market cap $198.17B). The key difference: Crowdstrike Holdings Inc is far larger — about 530.8× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | CRWD | |
|---|---|---|
Market Cap | $373.32M | $198.17B |
Sector | Health | Technology |
52-Week High | $7.23 | $199.38 |
52-Week Low | $4.17 | $87.56 |
Enterprise Value | $228.22M | $194.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CrowdStrike (CRWD) trades at $194.62, up 0.43% today, with a strong technical outlook showing bullish momentum and key resistance at $199. The stock recently completed a 4-for-1 split, enhancing accessibility. Revenue growth accelerated to 26% year-over-year in Q1 2026, with EPS consistently beating estimates, though net margins remain negative. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $180.33 consensus target, despite premium valuations like a P/E of 765.
Outlook remains optimistic due to robust cybersecurity demand and AI-driven threats, but high valuation and profitability challenges pose risks. Investors should weigh growth potential against elevated multiples and competitive pressures in the sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
